AstraZeneca Vaccine May Be Less Effective Against Indian Strain of COVID, Says UK Health Secretary sputniknews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sputniknews.com Daily Mail and Mail on Sunday newspapers.
Why India Needs To Locally Develop Critical Raw Materials For Vaccine Production
by Swarajya Staff - Apr 15, 2021 11:55 AM
Covid-19 vaccine - representative image (Twitter)
Snapshot
Shortage of crucial production inputs, including single-use bioreactor bags, beta propiolactone and thimerosal are threatening to scale down ambitious production targets of Indian Vaccine Manufacturers
In the wake of a shortage of raw materials to produce Covid-19 vaccines, Bharat Biotech Internationalâalong with Bengaluru based Biovet Private Ltd and Sapigen Biologix in Hyderabadâhas recently announced that it has tied up with the Council of Scientific and Industrial Research (CSIR).
Indian pharmaceutical company Bharat Biotech and top vaccine maker Serum Institute of India (SII) has been facing challenges after the United States and Europe banned the export of critical raw material required to produce vaccines.
How Do Sputnik V, Covaxin And Covishield Work? All You Need To Know
India on Monday became the 60th country to grant emergency use authorisation for Russia’s Sputnik V Covid-19 vaccine. File Photo Outlook Web Bureau 2021-04-14T07:43:43+05:30 How Do Sputnik V, Covaxin And Covishield Work? All You Need To Know outlookindia.com 2021-04-14T07:45:36+05:30
Also read
With an aim to expand the basket of Covid-19 vaccines and enhance the pace of inoculation in India, the central government on Tuesday said it has fast-tracked emergency approval for foreign-produced jabs that have been granted similar clearances in other countries. The first 100 beneficiaries of such foreign vaccines shall be assessed for seven days for safety outcomes before it is rolled out for further immunization programme within the country, the Union Health Ministry said.
What we know about India s coronavirus vaccines
Sun Online Desk
India s Covaxin, the homegrown government-backed vaccine, has an efficacy rate of 81%, preliminary data from its phase 3 trial shows.
India s regulators gave the vaccine an emergency approval in January while the third phase of the trial was still under way, sparking scepticism and questions from experts.
Bharat Biotech, the vaccine s manufacturer, said the latest findings were an important milestone in vaccine discovery, for science and our fight against coronavirus . With today s results from our phase 3 clinical trials, we have now reported data on our Covid-19 vaccine from phase 1, 2, and 3 trials involving around 27,000 participants, the firm said.
The U.S. new cases 7-day rolling average are 4.8 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 15.2 %
LOWER than the rolling average one week ago. Today s posts include:
U.S. Coronavirus New Cases are 54,434
U.S. Coronavirus deaths are at 1,245
U.S. Coronavirus immunizations have been administered to 33.1 % of the population
The 7-day rolling average rate of growth of the pandemic shows new cases worsened and deaths improved
What we know about India s Covid-19 vaccine
AstraZeneca Vax Flops Against South African Variant in Early Trial
Some long-haul covid-19 patients say their symptoms are subsiding after getting vaccines